Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:

NCT ID: NCT03629158 Not yet recruiting - Clinical trials for Coronary Artery Disease

Brief Behavioral Health Intervention Program for Patients With Stable Coronary Artery Disease

Start date: August 15, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the effectiveness of a lifestyle intervention for patients living with stable coronary artery disease (CAD). One group will receive the the intervention, and the other will receive treatment as usual (TAU). The investigators hypothesize that, compared to the TAU group, participants receiving the intervention will 1) experience greater confidence in managing their cardiac disease, as indicated by perceived self-efficacy and illness perceptions; 2) experience greater psychological adjustment as indicated by depressive, anxious, and demoralization symptoms; 3) experience greater engagement in health behaviors including healthy eating and physical activity.

NCT ID: NCT03627455 Completed - Clinical trials for Coronary Artery Disease

Troponin I and T and Adverse Outcomes in Patients With and Without Diabetes Mellitus After Coronary Intervention

Start date: January 1, 2003
Phase:
Study type: Observational

Elevated levels of troponin are associated with future MACE. Data on the prognostic value of high sensitive troponin T (hs-TnT) as compared to high sensitive troponin I (hs-TnI) in diabetic and non-diabetic patients are sparse. We aimed to assess the risk for MACE according to gender and diabetes status and to compare the prognostic value of hs-TnT and hs-TnI with regards to clinical outcomes in diabetic and non-diabetic patients undergoing percutaneous coronary intervention (PCI).

NCT ID: NCT03625908 Not yet recruiting - Clinical trials for Coronary Artery Disease

Optical Coherence Tomography-guided Coronary Intervention and Optimal Use of Dual Anti-Platelet Therapy In Patients With Complex Lesions (OCCUPI Trial)

Start date: August 15, 2018
Phase: N/A
Study type: Interventional

There is no definite conclusive work about optimal duration of DAPT after PCI of complex lesions, which have been left at each operator's discretion. It is needed to be investigated how optimal duration of dual antiplatelet therapy will be decided in complex lesions. Also, the benefit of OCT-guided PCI assuming better stent optimization should be determined in complex PCI. In the study, we will explore the clinical implication of OCT-guided PCI of complex lesions. Optimal duration of DAPT after PCI of complex lesions with or without OCT-guidance will be also investigated.

NCT ID: NCT03622671 Not yet recruiting - Clinical trials for Coronary Artery Disease

Fibrin Clot Properties and Blood Loss Following Coronary Artery By-pass Grafting

Start date: August 13, 2018
Phase: N/A
Study type: Interventional

Up to 15% of operations in cardio-pulmonary by-pass are complicated by excessive postoperative blood loss, which negatively affects the outcomes. Recently, it has been demonstrated that fibrin clot susceptibility to lysis is a modulator of postoperative blood loss after cardiac surgery for aortic stenosis. Earlier, a preliminary study showed a negative association of postoperative blood loss after coronary artery by-pass grafting (CABG) with fibrin clot lysis time, reflecting susceptibility to fibrinolysis. In CABG, postoperative blood loss may depend on the operative technique with respect to left internal mammary artery (LIMA) harvesting. LIMA is taken down in virtually all CABG procedures, but harvesting technical details remain at surgeons discretion (skeletonization without opening the pleural cavity vs. pedicled graft with pleura wide open). The investigators decided to test the hypothesis that fibrin clot properties modulate the postoperative drainage following CABG strongly enough to attenuate the influence of surgical technique by randomizing the patients undergoing CABG with regard to LIMA harvesting technique.

NCT ID: NCT03622203 Completed - Coronary Disease Clinical Trials

Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent

CHANCE
Start date: January 1, 2016
Phase:
Study type: Observational [Patient Registry]

Length of DAT (Dual Antiplatelet therapy) represents one of the most challenging choices for interventional cardiologist. Prolonged DAT reduces risk of subsequent MI (Myocardial Infarction) with an increase in major bleedings, consequently with a neutral effect on survival [1]. Recently a Polymer-free Drug-Coated coronary stent has been tested in a randomized controlled trial with only one month of DAT due to its peculiar features, with an increased efficacy compared to BMS (Bare Metal Stent) and with a not negligible risk of ST at one year (about 2%)[2,3]. The RCT despite its promising design (inclusion of high risk patients like those with previous bleeding or with severe renal disease) showed a major limitation, that is: 1. patients who are often offered a Biofreedom in real life, that is those with active cancer or needing major surgery or on OAT (Oral Anticoagulation) 2. and patients with bifurcation and multivessel disease, that is those with an increased risk of ST [4] 3. STEMI patients [5] were underrepresented (less than 30%). Consequently we performed this multicenter study to evaluate safety and efficacy of Biofreedom in real life patients. POCE (a composite end point of death, myocardial infarction, target lesion revascularization) and DOCE (cardiac death, MI-TLR and TLR) will be the primary end points, while its single components will be the secondary ones along stent thrombosis and with bleedings (Barc classification). At least 12 months The Leaders FREE (2) reported an incidence of MACE of 9.4% at one year in overall patients. If there is a true difference in favour of the experimental treatment of 1.2%, then 870 patients are required to be 80% sure that the upper limit of a one-sided 95% confidence interval (or equivalently a 90% two-sided confidence interval) will exclude a difference when compared to non selected patients of more than 2% [5] All patients implanting Biofreedom with these prespecified analysis: 1. Clinical - Diabetic patients (both insulin and not insulin depenent) - Requiring oral anticoagulation - On active cancer (that is requiring chemio or radio-therapy and or surgery) - Requiring surgery - STEMI 2. Interventional - Bifurcation (both provisional both 2 stents) - Multivessel - Ostial

NCT ID: NCT03620539 Not yet recruiting - Clinical trials for Coronary Artery Disease

Sauna Bathing to Improve Vascular Health of Adults With Heart Disease

Start date: September 2018
Phase: N/A
Study type: Interventional

This study is a clinical trial that will determine if sauna bathing improves blood vessel health in adults aged 50-70 years with heart disease.

NCT ID: NCT03619395 Not yet recruiting - Clinical trials for Acute Coronary Syndrome

Risc Optimisation- Acute cor5onary Syndrome

RiskOp-ACS
Start date: September 1, 2018
Phase:
Study type: Observational [Patient Registry]

This study evaluates the percentage of patients that reach the objective levels of LDL cholesterol, glycosylated hemoglobin and blood pressure recommended by clinical guidelines after an acute coronary syndrome, following strategies of pharmacological optimization based on algorithms. The investigators hypothesize that the use of algorithms designed and protocolized within a cardiac rehabilitation program after an ACS to optimize pharmacological treatment is effective and safe to improve the control of risk factors in patients with high cardiovascular risk.

NCT ID: NCT03618108 Recruiting - Clinical trials for Coronary Heart Disease

Anti-chlamydophila Antibiotic Combination Therapy in the Treatment of Patients With Coronary Heart Disease

ACAC-CHD
Start date: April 4, 2018
Phase: Phase 2
Study type: Interventional

The purpose of the study is to see whether the antibiotic combination of 100mg doxycycline, 500mg azithromycin and 300mg rifabutin is a safe and effective treatment for coronary artery disease which has not responded to 'standard treatment'. Coronary artery disease is the process of plaque build up within the walls of the arteries responsible for supplying the heart with oxygen and nutrients. plaque is usually made up of fatty deposits, minerals and various amounts of tissue and white cells which eventually narrows the artery, reducing blood flow to the heart. The resulting damage and build up of fat leads to inflammation of the arterial wall and eventually the arteries narrow. The researchers involved in this study consider that a pathogen called Chlamydophila pneumoniae, which can live inside cells may cause this inflammation of the arterial wall. The purpose of this study is to see if treatment with this antibiotic combination in patients with CHD is safe and effective in reducing disease severity measured at coronary angiography and improving quality of life. Approximately 60 patients will be involved in this trial. the treatment period is 90 days with a further 90 day follow up period.

NCT ID: NCT03615963 Completed - Clinical trials for Coronary Artery Disease

Aortic Stiffness and Distensibility as Predictor to Severity of Coronary Artery Disease

Start date: October 1, 2017
Phase:
Study type: Observational

Assess the relationship of Aortic root distensibility and stiffness with the extent of coronary artery disease as assessed by SYNTAX score compared to a matched cohort of patients with normal coronary angiography

NCT ID: NCT03613337 Recruiting - Clinical trials for Coronary Heart Disease

Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention

Start date: May 1, 2018
Phase:
Study type: Observational

Restenosis occurs for many different reasons. Over the years, many predictive clinical, biological, genetic, epigenetic, lesion-related, and procedural risk factors for restenosis have been identified. Smoking is one of most important factors, however the results were contradictory. And the genetic factors of restenosis have been studied mostly in European populations. Based on literature review, study of candidate genes for restenosis in Chinese population was insufficient. With due attention to this matter mentioned above, the investigators aim to preliminary explore genetic variation and smoking effect on clinical restenosis in patients diagnosed with after percutaneous coronary intervention in the Chinese population, with correlation analysis of factors and gene-set analysis of biological pathways related to restenosis and platelet approach were widely used in this study.